| dc.contributor.author | Ge, Derek | |
| dc.contributor.author | Foer, Dinah | |
| dc.contributor.author | Cahill, Katherine N. | |
| dc.date.accessioned | 2023-01-25T18:59:05Z | |
| dc.date.available | 2023-01-25T18:59:05Z | |
| dc.date.issued | 2022-12-08 | |
| dc.identifier.issn | 2364-1754 | |
| dc.identifier.other | eISSN 2364-1746 | |
| dc.identifier.other | PubMed ID36575356 | |
| dc.identifier.uri | http://hdl.handle.net/1803/17948 | |
| dc.description.abstract | Adults with obesity may develop asthma that is ineffectively controlled by inhaled corticosteroids and long-acting beta-adrenoceptor agonists. Mechanistic and translational studies suggest that metabolic dysregulation that occurs with obesity, particularly hyperglycemia and insulin resistance, contributes to altered immune cell function and low-grade systemic inflammation. Importantly, in these cases, the same proinflammatory cytokines believed to contribute to insulin resistance may also be responsible for airway remodeling and hyperresponsiveness. In the past decade, new research has emerged assessing whether hypoglycemic therapies impact comorbid asthma as reflected by the incidence of asthma, asthma-related emergency department visits, asthma-related hospitalizations, and asthma-related exacerbations. The purpose of this review article is to discuss the mechanism of action, preclinical data, and existing clinical studies regarding the efficacy and safety of hypoglycemic therapies for adults with obesity and comorbid asthma. | en_US |
| dc.description.sponsorship | No funding or sponsorship was
received for this study or publication of this
article. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Pulmonary Therapy | en_US |
| dc.rights | This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License, which permits
any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium
or format, as long as you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons licence, and
indicate if changes were made. The images or
other third party material in this article are
included in the article’s Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included
in the article’s Creative Commons licence and
your intended use is not permitted by statutory
regulation or exceeds the permitted use, you
will need to obtain permission directly from the
copyright holder. To view a copy of this licence,
visit http://creativecommons.org/licenses/by-
nc/4.0/. | |
| dc.source.uri | https://link.springer.com/content/pdf/10.1007/s41030-022-00211-x.pdf | |
| dc.subject | Body mass index | en_US |
| dc.subject | DPP-4 inhibitors | en_US |
| dc.subject | GLP-1R agonists | en_US |
| dc.subject | Incretins | en_US |
| dc.subject | Insulin | en_US |
| dc.subject | Metformin | en_US |
| dc.subject | SGLT-2 inhibitors | en_US |
| dc.subject | Sulfonylureas | en_US |
| dc.subject | Thiazolidinediones | en_US |
| dc.subject | Type 2 diabetes | en_US |
| dc.title | Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1007/s41030-022-00211-x | |
